Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RGC
RGC logo

RGC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
6.100
Open
5.600
VWAP
5.74
Vol
417.08K
Mkt Cap
2.95B
Low
5.170
Amount
2.39M
EV/EBITDA(TTM)
--
Total Shares
495.47M
EV
2.78B
EV/OCF(TTM)
--
P/S(TTM)
--
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Show More

Events Timeline

(ET)
2026-07-01
12:30:00
Regencell Bioscience Stock Rises 29.6% to $7.89
select
2026-06-26 (ET)
2026-06-26
12:30:00
Regencell Bioscience Shares Drop 16% to $6.29
select
2026-06-26
10:30:00
Regencell Bioscience Shares Down 11.5% to $6.63
select
2026-06-25 (ET)
2026-06-25
12:30:00
Regencell Bioscience Shares Down 13.6% to $7.40
select
2026-06-24 (ET)
2026-06-24
12:30:00
Regencell Bioscience Shares Down 14.3% to $9.50
select
2026-06-17 (ET)
2026-06-17
12:30:00
Regencell Bioscience Shares Down 14.7% to $14.27
select
2026-04-07 (ET)
2026-04-07
12:10:00
Regencell Bioscience Shares Down 10.7% to $27.52
select
2026-04-07
10:10:00
Regencell Bioscience Shares Down 7.1% to $28.64
select
2026-04-02 (ET)
2026-04-02
12:10:00
Regencell Bioscience Shares Down 9.5% to $30.50
select
2026-04-01 (ET)
2026-04-01
12:10:00
Regencell Bioscience Stock Rises 49.5% to $38.02
select

News

seekingalpha
2.0
07-01seekingalpha
Regencell Bioscience Shares Surge 35% Amid Short Squeeze
  • Short Squeeze Effect: Regencell Bioscience shares surged approximately 35% amid a significant short squeeze, with trading volume reaching about 2.18 million shares by 2:25 PM ET, far exceeding the average daily volume of 151,000 shares.
  • Year-to-Date Decline: Despite today's notable increase, Regencell is down roughly 61% year-to-date, indicating ongoing pressure on the company that may affect investor confidence moving forward.
  • Annual Return Drop: Over the past year, Regencell's stock has declined about 44%, reflecting long-term challenges that could lead investors to reassess the company's future growth potential.
  • Increased Market Attention: This price volatility has drawn market attention to Regencell, prompting investors to closely monitor its subsequent performance and potential fundamental changes to make more informed investment decisions.
PRnewswire
7.0
06-23PRnewswire
Regencell Bioscience Faces Class Action Lawsuit
  • Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting serious concerns over the company's compliance and operational transparency.
  • Allegations of False Statements: The complaint alleges that during the class period, defendants made materially false and misleading statements and failed to disclose the true state of the company's business and compliance policies, potentially misleading investors and impacting their returns.
  • Investor Rights Protection: Affected investors are encouraged to apply to be lead plaintiffs by June 23, 2026, indicating the legal team's commitment to protecting investor rights while emphasizing the proactive role investors can take in the legal process.
  • No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers contingency fee arrangements, meaning investors do not incur upfront costs and only pay attorney fees upon successful recovery, thereby reducing the financial burden on investors.
Globenewswire
7.0
06-23Globenewswire
Regencell Bioscience Class Action Alert for Investors
  • Class Action Notice: The Portnoy Law Firm advises investors of Regencell Bioscience Holdings Limited (NASDAQ: RGC) regarding a class action for those who purchased securities between October 28, 2024, and October 31, 2025, with a deadline to file a lead plaintiff motion by June 23, 2026.
  • Market Manipulation Risks: The complaint alleges that Regencell failed to disclose its vulnerability to market manipulation during the class period, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny and enforcement actions.
  • Rising Legal Costs: On October 31, 2025, Regencell revealed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to recent market volatility, indicating potential significant legal costs and fines that may exceed any insurance coverage.
  • Stock Price Plunge: Following this news, Regencell's ordinary share price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, highlighting the market's uncertainty about the company's future and a decline in investor confidence.
PRnewswire
7.0
06-23PRnewswire
Regencell Securities Class Action Reminder
  • Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to potentially receive compensation without any out-of-pocket fees.
  • Counsel Selection: Investors are encouraged to choose qualified counsel with a proven track record, as Rosen Law Firm is recognized for its success in securities class actions, having ranked No. 1 in 2017 for settlements according to ISS Securities Class Action Services.
  • Case Background: The lawsuit alleges that Regencell made false or misleading statements during the class period, exposing investors to market manipulation and significant financial risks, along with potential regulatory scrutiny and legal repercussions affecting the company's reputation.
  • Investor Losses: As the true details emerged, investors suffered damages, and Rosen Law Firm aims to secure compensation for affected investors, ensuring their rights are protected.
Globenewswire
7.0
06-22Globenewswire
Regencell Faces Class Action Lawsuit for Investor Rights
  • Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, highlighting potential legal liabilities for the company.
  • Allegations of False Statements: The lawsuit alleges that Regencell and its executives failed to disclose significant adverse facts regarding the company's operations and compliance policies, exposing investors to substantial financial risks and raising concerns about the company's transparency.
  • Market Manipulation Risks: The lawsuit mentions that Regencell's stock was subject to market manipulation, resulting in increased volatility that not only undermined investor confidence but also could trigger further scrutiny from regulatory bodies.
  • Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, underscoring the importance of this case in protecting investor rights, with the law firm offering free consultations to encourage more affected investors to participate.
Globenewswire
7.0
06-22Globenewswire
Multiple Companies Face Class Action Lawsuits
  • LKQ Corporation Lawsuit: LKQ Corporation is facing a class action lawsuit for failing to disclose significant risks regarding customer losses and declining market share during the period from February 27, 2023, to July 23, 2025, with a lead plaintiff deadline of June 22, 2026, potentially impacting the company's reputation and stock price.
  • Regencell Bioscience Lawsuit: Regencell Bioscience Holdings Limited is accused of failing to disclose market manipulation risks from October 28, 2024, to October 31, 2025, exposing investors to significant financial risks, with a lead plaintiff deadline of June 23, 2026, which may trigger regulatory scrutiny.
  • Globant S.A. Lawsuit: Globant S.A. is under scrutiny for not disclosing decreasing demand and project cancellations in Latin America from February 15, 2024, to August 14, 2025, leading to investor losses, with a lead plaintiff deadline of June 23, 2026, which could negatively affect future performance.
  • Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors that they can contact the firm to discuss their legal rights if they suffered losses during the specified periods, which may influence their legal options and subsequent actions.

Valuation Metrics

The current forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Regencell Bioscience Holdings Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

ARE QUANTUM STOCKS GOING DOWN
Intellectia · 29 candidates
Rsi Category: moderateRelative Vol: >= 1.50Moving Average Relationship: PriceBelowMA20, PriceBelowMA200Month Price Change Pct: <= $0.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 1,000,000Macd: bearish
Ticker
Name
Market Cap$
top bottom
WOK logo
WOK
WORK Medical Technology Group Ltd
191.43K
LICN logo
LICN
Lichen International Ltd
17.75M
ZEPP logo
ZEPP
Zepp Health Corp
129.05M
FUTU logo
FUTU
Futu Holdings Ltd
15.10B
TIGR logo
TIGR
UP Fintech Holding Ltd
894.39M
CRBP logo
CRBP
Corbus Pharmaceuticals Holdings Inc
210.29M
okay give me some I can buy
Intellectia · 8 candidates
Market Cap: >= 10.00BRegion: USPrice: $5.00 - $60.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $20.00Monthly Average Dollar Volume: >= 5,000,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
11.85B
AMKR logo
AMKR
Amkor Technology Inc
13.66B
SKM logo
SKM
SK Telecom Co Ltd
13.67B
SBS logo
SBS
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP
23.76B
STLA logo
STLA
Stellantis NV
29.78B
RGC logo
RGC
Regencell Bioscience Holdings Ltd
13.93B
stick of the week
Intellectia · 10 candidates
Market Cap: >= 10.00BRsi Category: moderateMoving Average Relationship: PriceAboveMA200Week Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
12.12B
SBAC logo
SBAC
SBA Communications Corp
22.64B
INTC logo
INTC
Intel Corp
254.58B
STX logo
STX
Seagate Technology Holdings PLC
96.19B
CIEN logo
CIEN
Ciena Corp
61.40B
LITE logo
LITE
Lumentum Holdings Inc
55.14B
what should I buy for swing trading
Intellectia · 426 candidates
Price: $10.00 - $150.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $40.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MLEC logo
MLEC
Moolec Science SA
5.05M
AEHR logo
AEHR
Aehr Test Systems
1.36B
BKSY logo
BKSY
Blacksky Technology Inc
1.14B
LUNR logo
LUNR
Intuitive Machines Inc
5.20B
KRRO logo
KRRO
Korro Bio Inc
201.92M
SNSE logo
SNSE
Sensei Biotherapeutics Inc
41.58M
top moving stocks
Intellectia · 31 candidates
Market Cap: >= 500.00MPrice: >= $2.00Price Change Pct: $-100.00 - $-5.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
LNN logo
LNN
Lindsay Corp
1.22B
KNF logo
KNF
Knife River Corp
4.65B
OMER logo
OMER
Omeros Corp
869.71M
WIX logo
WIX
Wix.Com Ltd
5.28B
IRWD logo
IRWD
Ironwood Pharmaceuticals Inc
635.93M
PBH logo
PBH
Prestige Consumer Healthcare Inc
2.73B
stocks gain $5.00 in 2026
Intellectia · 2622 candidates
Year Price Change Pct: >= $0.01
Ticker
Name
Market Cap$
top bottom
AXTI logo
AXTI
AXT Inc
3.80B
PTN logo
PTN
Palatin Technologies Inc
35.18M
RGC logo
RGC
Regencell Bioscience Holdings Ltd
12.08B
RLMD logo
RLMD
Relmada Therapeutics Inc
639.83M
BW logo
BW
Babcock & Wilcox Enterprises Inc
1.95B
TERN logo
TERN
Terns Pharmaceuticals Inc
5.44B
bullish stocks this week
Intellectia · 56 candidates
Market Cap: >= 4.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MASI logo
MASI
Masimo Corp
9.43B
IBRX logo
IBRX
Immunitybio Inc
8.41B
ONDS logo
ONDS
Ondas Inc
4.98B
MRNA logo
MRNA
Moderna Inc
18.21B
ELF logo
ELF
elf Beauty Inc
5.20B
KTOS logo
KTOS
Kratos Defense and Security Solutions Inc
17.84B
ابي سهم التارقت حقي يكون اجيب فوق 25% واعلى من راس مالي
Intellectia · 1346 candidates
Year Price Change Pct: >= $25.00
Ticker
Name
Market Cap$
top bottom
RGC logo
RGC
Regencell Bioscience Holdings Ltd
13.54B
PTN logo
PTN
Palatin Technologies Inc
28.78M
ANPA logo
ANPA
Rich Sparkle Holdings Ltd
875.38M
ABVX logo
ABVX
Abivax SA
8.86B
SNDK logo
SNDK
Sandisk Corp
97.55B
HYMC logo
HYMC
Hycroft Mining Holding Corporation
3.20B
what’s a good buy for day trading
Intellectia · 2418 candidates
Region: USPrice: $2.00 - $200.00Volume: >= 200,000List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
AZN logo
AZN
AstraZeneca PLC
298.35B
PLAG logo
PLAG
Planet Green Holdings Corp
30.35M
AQST logo
AQST
Aquestive Therapeutics Inc
509.36M
CATX logo
CATX
Perspective Therapeutics Inc
351.47M
ASTI logo
ASTI
Ascent Solar Technologies Inc
29.36M
PAVM logo
PAVM
PAVmed Inc
9.16M
entonces que acciones?
Intellectia · 74 candidates
Market Cap: >= 3.00BRsi Category: moderateWeek Price Change Pct: $5.00 - $20.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SSL logo
SSL
Sasol Ltd
4.76B
LMND logo
LMND
Lemonade Inc
6.97B
TEO logo
TEO
Telecom Argentina SA
5.50B
SBS logo
SBS
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP
18.55B
KEP logo
KEP
Korea Electric Power Corp
27.73B
PKX logo
PKX
Posco Holdings Inc
19.18B

Whales Holding RGC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Regencell Bioscience Holdings Ltd (RGC) stock price today?

The current price of RGC is 5.95 USD — it has increased 6.06

What is Regencell Bioscience Holdings Ltd (RGC)'s business?

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

What is the price predicton of RGC Stock?

Wall Street analysts forecast RGC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regencell Bioscience Holdings Ltd (RGC)'s revenue for the last quarter?

Regencell Bioscience Holdings Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Regencell Bioscience Holdings Ltd (RGC)'s earnings per share (EPS) for the last quarter?

Regencell Bioscience Holdings Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Regencell Bioscience Holdings Ltd (RGC). have?

Regencell Bioscience Holdings Ltd (RGC) has 10 emplpoyees as of July 08 2026.

What is Regencell Bioscience Holdings Ltd (RGC) market cap?

Today RGC has the market capitalization of 2.95B USD.